https://assets.capyfin.com/instruments/678fdc13234e27009c5d5cca.png avatar
Boston Scientific
🇺🇸 NYSE:BSX
View Company
OverviewEarningsDividends
•
Dec 31, 2023

Boston Scientific Q4 2023 Earnings Report

Boston Scientific reported strong Q4 2023 results, exceeding guidance and demonstrating growth across all segments and regions.

Key Takeaways

Boston Scientific announced net sales of $3.725 billion for Q4 2023, a 14.9% increase on a reported basis compared to the prior year period. GAAP net income attributable to Boston Scientific common stockholders was $504 million, or $0.34 per share, while adjusted EPS reached $0.55. The company exceeded its guidance range for both net sales growth and EPS.

Net sales increased by 14.9% on a reported basis, reaching $3.725 billion.

GAAP net income attributable to Boston Scientific common stockholders was $504 million, or $0.34 per share.

Adjusted EPS was $0.55 per share, surpassing the company's guidance.

The company achieved double-digit net sales growth across all reportable segments and regions.

Total Revenue
$3.73B
Previous year: $3.24B
+14.9%
EPS
$0.55
Previous year: $0.45
+22.2%
MedSurg Organic Revenue Growth
8.9%
Previous year: 8.5%
+4.7%
Cardio Organic Revenue Growth
13.3%
Previous year: 9.4%
+41.5%
Gross Profit
$2.58B
Previous year: $2.23B
+15.6%
Cash and Equivalents
$865M
Previous year: $928M
-6.8%
Free Cash Flow
$690M
Previous year: $595M
+16.0%
Total Assets
$35.1B
Previous year: $32.5B
+8.2%

Boston Scientific

Boston Scientific

Boston Scientific Revenue by Segment

Boston Scientific Revenue by Geographic Location

Forward Guidance

The company estimates net sales growth for the full year 2024 to be approximately 8.5 to 9.5 percent on a reported basis, and approximately 8 to 9 percent on an organic basis. The company estimates EPS on a GAAP basis in a range of $1.38 to $1.42 and estimates adjusted EPS of $2.23 to $2.27.

Positive Outlook

  • Full year 2024 net sales growth is expected to be in the range of 8.5% to 9.5% on a reported basis.
  • Full year 2024 organic net sales growth is projected to be between 8% and 9%.
  • Full year 2024 EPS is estimated to be in the range of $1.38 to $1.42 on a GAAP basis.
  • Full year 2024 adjusted EPS is projected to be between $2.23 and $2.27.
  • First quarter 2024 net sales growth is expected to be in the range of 7.5% to 9.5% on a reported basis.

Challenges Ahead

  • First quarter 2024 organic net sales growth is expected to be between 7% and 9%.
  • First quarter 2024 EPS is estimated to be in the range of $0.29 to $0.31 on a GAAP basis.
  • First quarter 2024 adjusted EPS is projected to be between $0.50 and $0.52.
  • Full year organic net sales guidance excludes the impact of foreign currency fluctuations.
  • First quarter organic net sales guidance excludes the impact of foreign currency fluctuations.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Boston Scientific